Biktarvy® for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/04/2018|
|Rapid review completed||07/06/2018|
|Rapid Review outcome||Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.|
The HSE has approved reimbursement following confidential price negotiations December 2018.